Global Vaccine Adjuvants Market by Product Type (Adjuvant Emulsion, Particulate Adjuvants, and Pathogen Components), By Route of Administration (Oral, Subcutaneous, Intradermal, Intramuscular, and Intranasal), By Application (Research and Commercial), By Region and Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends, and Forecast 2023-2032

Report Overview

The global vaccine adjuvants market size is expected to be worth around USD 1,134.7 Million by 2022 from USD 3,933.7 Million in 2032, growing at a CAGR of 13.6% during the forecast period from 2022 to 2032.

A vaccine adjuvant is an agent that raises a specific immune response to an antigen. Therefore, adjuvants are added to vaccines to increase their ability to include long-term protection against infections. Adjuvants for vaccines are currently in development, and the only adjuvants that are feasible for human use are aluminum salts and MF59.

After the creation of the latest generation of vaccines, research & development for potent vaccine adjuvants is moving at a breakneck pace. Because vaccines are less immunogenic, they require more potent adjuvants. This must have resulted in significant investments made by researchers and scientists in research & development (R&D) for vaccine adjuvants that are both safe and effective, thereby boosting market expansion.

*Actual Numbers Might Vary In The Final Report

Key Takeaways

• Increased Demand: The vaccine adjuvants market has experienced exponential expansion due to an ever-increasing need for effective and potency vaccines.
• Diverse Applications: Adjuvants can enhance the efficacy of numerous vaccines, including influenza, hepatitis and HPV vaccination programs to maximize effectiveness.
• Safety and Regulatory Oversight: All adjuvants used in vaccines undergo thorough safety testing before being approved for use, with health authorities such as FDA or WHO conducting oversight checks to make sure that safety standards are being met.
• Market Competition: The vaccine adjuvant market is highly competitive, with multiple suppliers providing various formulations of adjuvants.
• Focus on Research and Development: Current research and development initiatives aim to create novel adjuvants which will further increase vaccine efficacy while decreasing side effects.
• Side Effects of Adjuvanted Vaccines: While adjuvanted vaccines typically cause only minor or temporary side effects, monitoring and reporting adverse events is still vitally important to ensuring vaccine safety.

Product Type Analysis

Particulate Adjuvants Segment Held the Largest Market Share of the Global Vaccine Adjuvants Market

Based on product type, the global vaccine adjuvants market is segmented into adjuvant emulsion, particulate adjuvants, and pathogen components. The particulate adjuvants segment accounted for the largest market share of 33.4% in 2022. Attributed to the presence of a wide range of products and greater efficiency against diseases.

Particulate adjuvants type includes adjuvants consisting of alum, cytokines, and virosomes. Alum is the most often used adjuvant containing aluminum salts. It is used in HPV vaccines, and hepatitis B. Virosomes are particles resembling non-infectious viruses used as adjuvants in hepatitis A, influenza vaccine Inflexal, and Epaxal.

On the other hand, the pathogen components type segment is anticipated to be the fastest growing during the forecast period. Some of the pathogenic adjuvants tested comprise monophosphoryl lipid A. It is combined with alum to produce ASO4 adjuvant, used in an HPV-Cervarix.

By Route of Administration Analysis

Intramuscular Segment Accounted for the Highest the Market Growth During the Forecast Period

Based on the route of administration, the global vaccine adjuvants market is divided into oral, subcutaneous, intradermal, intramuscular, and intranasal. The intramuscular route is a leading segment that registers the highest market share during the forecast period. This includes vaccines for influenza, HPV, meningitis, etc.

The efficiency of vaccines depends upon the route of administration. For example, alum salts, the most extensively used parenteral adjuvants, are ineffective when administered by oral or nasal route.

Moreover, the intradermal route is anticipated to be the fast-increasing segment owing to a longer absorption period and time of action related to other routes, raising the requirement for vaccines administered through this route.

By Application Analysis

Research Segment Dominates the Vaccine Adjuvants Market Growth During the Forecast Period

Based on application, the global vaccine adjuvants market is divided into research and commercial. The research segment is the fastest-growing segment anticipated to account for a major market revenue share of 54% during the forecast period. It is projected to maintain its dominance due to various research institutes and government organizations for R &D of adjuvants and vaccines.

The commercial segment is anticipated to witness robust growth during the forecast years. Attributed to the increasing initiatives by government bodies and companies and the rise in the use of various vaccine adjuvants commercially.

Key Market Segments

By Product Type

• Adjuvant Emulsion
• Particulate Adjuvants
• Pathogen Components

By Route of Administration

• Oral
• Subcutaneous
• Intramuscular
• Intradermal
• Intranasal

By Application

• Research
• Commercial

Drivers

The Increasing Demand for Vaccines and the Occurrence of New Diseases Drive the Vaccine Adjuvants Market Growth.

Across the world, the consumption of vaccines is rising as it is one of the effective ways to be protected from various diseases. Several governments have been conducting various programs to promote vaccination among people, and the awareness levels among individuals regarding the advantages associated with vaccinations have improved, which is estimated to result in the growth of the vaccine adjuvants market.

In addition, the growing prevalence of infectious and zoonotic diseases has an increasing focus on vaccination programs by several government bodies. Increasing focus on enhanced and long-term immunization further current and emerging diseases is accelerating the growth rate of the global vaccine adjuvant market. However, rising R&D government expenditure, agreements, and associations by market participants are other notable factors driving market growth.

The increasing demand for vaccine adjuvants market potential in developing countries offers various growth possibilities to the adjuvant vaccine manufacturers and the major key players in the market drivers. The growing elderly population is a major factor driving the growth of the vaccine adjuvants market.

Restraints

Side Effects with Adjuvants and High Toxicity are the Major Restraints to The Global Vaccine Adjuvant Market

Moreover, high toxicity adjuvants and adverse effects associated with adjuvants are primary restraints to the global vaccine adjuvant market. High costs associated with adjuvant-based research and established protection are restraining market growth. The denying effects of adjuvants toxicity on the vaccines manufacturing cost and protective profiles inhibits the growing market demand.

The high toxicity adjuvants factors and side effects impending the vaccine adjuvant market growth during the forecast period.  However, insufficient knowledge among humans and inadequate healthcare facilities hindered the growing market share. Fewer research activities in its development also hamper the market growth.

Opportunity

Government Initiatives for Immunization are Anticipated to Offered Significant Growth Opportunities

The outbreak of the COVID-19 pandemic across the world is anticipated to provide significant growth opportunities for key players in the vaccine adjuvants market. For example, with the rising focus on the development of coronavirus disease(COVID-19). The use of vaccine adjuvants has also increased across the globe.

Government policies for immunization are projected to offer significant growth opportunities for key players in the global vaccine adjuvants market. For example, immunization is one of the world’s most lucrative public health involvement, saving millions of lives each year. The Government of India has implemented the largest immunization program globally.

Trends

Aluminum-Based Salts are Trends Anticipated in the Market During the Forecast Period.

Adjuvants such as aluminum salts are used as additives in vaccines to improve immune responses. Aluminum salts include such as aluminum potassium sulfate, aluminum phosphate, and aluminum hydroxide. However, aluminum-based salts are also used for research purposes to improve the effectiveness of vaccines. This trend is anticipated to continue during the forecast period, driving the global vaccine adjuvants market.

Market analysts have closely tracked vaccine adjuvants market trends over recent years. Analysts have seen steady increases in demand due to rising need for effective and safe vaccines as well as rising infectious disease prevalence rates. Furthermore, industry observers have witnessed a trend toward creating novel adjuvants which enhance immune response while increasing vaccine efficacy.

However, with the rising burden of infectious diseases across the world, the use of vaccine adjuvants is also growing rapidly. The dominance of infectious diseases globally is increasing fastly owing to various factors, which in turn has raised the use of vaccine adjuvants as vaccination is one of the effective approaches for the prevention of infectious disease.

Regional Analysis

North American region accounted Significant Revenue Share of the Global Vaccine Adjuvants Market

North America accounted largest revenue share for the vaccine adjuvants market at 39%. The factors contributing to the growth of vaccine adjuvants in the North American region are increased investments in R&D of new therapeutics and an increase in serious widespread diseases. Thus primary to the need for immunization against chronic and acute diseases. Also, the key market players in the US raise the penetration of products.

The European vaccine adjuvant market has a significant global market share and is anticipated to progress considerably during the forecast period. Due to a rise in patients affected by diseases and infections. Asia- Pacific is also anticipated to witness lucrative growth in the global vaccine adjuvants market. Owing to the increase in the incidence of infectious diseases, the rise in the use of vaccine adjuvants, and government policies for immunization in the region.

Latin America is expected to have a consistent CAGR in the upcoming years. The growing awareness among the Latin American population about vaccination growing incidence of infectious diseases drives the regional market growth.  MEA is predicted to moderate share and grow slow CAGR during the forecast period.

Key Regions

• North America
  • The US
  • Canada
  • Mexico
• Western Europe
  • Germany
  • France
  • The UK
  • Spain
  • Italy
  • Portugal
  • Ireland
  • Austria
  • Switzerland
  • Benelux
  • Nordic
  • Rest of Western Europe
• Eastern Europe
  • Russia
  • Poland
  • The Czech Republic
  • Greece
  • Rest of Eastern Europe
• APAC
  • China
  • Japan
  • South Korea
  • India
  • Australia & New Zealand
  • Indonesia
  • Malaysia
  • Philippines
  • Singapore
  • Thailand
  • Vietnam
  • Rest of APAC
• Latin America
  • Brazil
  • Colombia
  • Chile
  • Argentina
  • Costa Rica
  • Rest of Latin America

• Middle East & Africa
  • Algeria
  • Egypt
  • Israel
  • Kuwait
  • Nigeria
  • Saudi Arabia
  • South Africa
  • Turkey
  • United Arab Emirates
  • Rest of MEA

Key Players Analysis

The major companies have conducted approvals, product launches, and collaborations to develop novel vaccine adjuvants, thus building a competitive landscape in the market. The vaccine adjuvants market moderately consists of many prominent major key players companies such as Merck KGaA, MPV Technologies, SPI Pharma, Agenus Inc., CSL Limited, and Adjuvant Technologies. These prominent market players focus on expanding business in developed regions to grow their market share.

Major Key Players

• Merck KGaA
• Dynavax Technologies Corporation
• Croda International Plc
• Novavax, Inc.
• CSL Limited
• AstraZeneca plc
• MPV Technologies LLC
• Adjuvance Technologies, Inc.
• SPI Pharma
• Agenus Inc.
• Astellas Pharma, Inc.
• CureVac N.V.
• Sanofi S.A.
• GlaxoSmithKline plc
• OZ Biosciences
• Vaxine Pty Ltd
• Merck & Co, Inc.
• Phibro Animal Health Corporation
• Brenntag Biosector
• Brenntag SE
• Other Key Players

 Recent Development

• February 2022- As the foundation for their regulatory applications for a COVID-19 vaccine, Sanofi and GSK aim to submit data from their promoter and Phase 3 efficacy trials.
• September 2021-Novavax Inc. enrolled the first participant in its Phase 1/2 study, evaluating the immunogenicity and safety of combination vaccines using Novavax influenza and COVID-19. Clinical trials include recombinant protein-based NanoFlu candidates and patented saponin-based Matrix – M adjuvant in a single formulation.

Report Scope